SPOTLIGHT -
Phase 2 Evaluating BDC-1001 Plus Perjeta in HER2-Positive Breast Cancer
Research is underway on the immune-stimulating antibody conjugate BDC-1001’s effectiveness against HER2-positive cancers when combined with Perjeta, according to data presented at SABCS.
Velcade and Rituxan Help Improve Responses in Marginal Zone Lymphoma
A treatment combination that includes Velcade and Rituxan helps improve responses and the safety profile in marginal zone lymphoma, according to a phase 2 trial.
Exercise Improves Physical Abilities in Patients With Multiple Myeloma
Patients with multiple myeloma who are undergoing systemic treatment can see improvements from exercise, a recent study shows.
